Brachytherapy
Volume 7, Issue 4 , Pages 290-296 , October 2008

Recommendations for permanent prostate brachytherapy with 131Cs: A consensus report from the Cesium Advisory Group

  • William S. Bice

      Affiliations

    • Foundation for Medical Physics Research, San Antonio, TX
    • UTHSCSA, San Antonio, TX
    • Corresponding Author InformationCorresponding author. Foundation of Medical Physics Research, 12822 Vista Haven, San Antonio, TX 78216, USA. Tel.: +1-210-860-1774; fax: +1-210-538-5457.
    • ,
  • Bradley R. Prestidge

      Affiliations

    • UTHSCSA, San Antonio, TX
    • Texas Cancer Clinic, San Antonio, TX
    • ,
  • Steven M. Kurtzman

      Affiliations

    • Dorothy E. Schneider Cancer Center, San Mateo, CA
    • ,
  • Sushil Beriwal

      Affiliations

    • Department of Radiation Oncology, UPMC Cancer Center, Pittsburgh, PA
    • ,
  • Brian J. Moran

      Affiliations

    • Prostate Cancer Foundation of Chicago, Westmont, IL
    • ,
  • Rakesh R. Patel

      Affiliations

    • Department of Human Oncology, University of Wisconsin, Madison, WI
    • ,
  • Mark J. Rivard

      Affiliations

    • Tufts University School of Medicine, Boston, MA

Received 9 February 2008 ,Revised 20 May 2008 ,Accepted 29 May 2008.

References 

  1. Armpilia CI, Dale RG, Coles IP, et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys. 2003;55:378–385
  2. Prestidge BR, Bice WS, Jurkovic I, et al. Cesium-131 permanent prostate brachytherapy: an initial report. Int J Radiat Oncol Biol Phys. 2005;63:S336–S337
  3. Prestidge BR, Bice WS, Jurkovic J, et al. A multi-institutional phase II trial for cesium-131 permanent prostate brachytherapy. Brachytherapy. 2006;5:79
  4. Bice WS, Prestidge BR. Cesium-131 permanent prostate brachytherapy: the dosimetric analysis of a multi-institutional phase II trial. Brachytherapy. 2007;6:88–89
  5. Prestidge BR, Bice WS. Clinical outcomes of a phase II, multi-institutional cesium-131 permanent prostate brachytherapy trial. Brachytherapy. 2007;6:78
  6. Rivard MJ. Brachytherapy dosimetry parameters calculated for a 131Cs source. Med Phys. Feb 2007;34:754–762
  7. Ibbott GS. Advice to customers of IsoRay 131Cs brachytherapy sources recommended dosimetry data. Personal communication. Richland, WA: IsoRayMedical; 2007.
  8. Dale RG. Comparison of the radiobiological effects of Cs-131 implants with those associated with I-125 and Pd-103 implants. Personal communication. Richland, WA: IsoRayMedical; 2004.
  9. Yue N, Heron DE, Komanduri K, et al. Prescription dose in permanent (131)Cs seed prostate implants. Med Phys. Aug 2005;32:2496–2502
  10. Murphy MK, Piper RK, Greenwood LR, et al. Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy. Med Phys. Jun 2004;31:1529–1538
  11. Chen Z, Bongiorni P, Nath R. Dose rate constant of a cesium-131 interstitial brachytherapy seed measured by thermoluminescent dosimetry and gamma-ray spectrometry. Med Phys. Nov 2005;32:3279–3285
  12. Wittman RS, Fisher DR. Multiple-estimate Monte Carlo calculation of the dose rate constant for a cesium-131 interstitial brachytherapy seed. Med Phys. Jan 2007;34:49–54
  13. Brenner DJ. Estimation of optimal Cs-131 boost dose for combined external-beam/boost treatment for prostate cancer; 2005.
  14. NUREG1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. 2002;9:U1–U27.
  15. 10 CFR35. Medical use of byproduct material: part 35.75 release of individuals containing unsealed byproduct material or implants containing byproduct material; 2007.
  16. Prestidge BR, Bice WS, Kiefer EJ, et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;40:1111–1115
  17. Waterman FM, Yue N, Corn BW, et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys. 1998;41:1069–1077
  18. Yue N, Dicker AP, Corn BW, et al. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate. Int J Radiat Oncol Biol Phys. 1999;43:447–454
  19. Speight JL, Shinohara K, Pickett B, et al. Prostate volume change after radioactive seed implantation: possible benefit of improved dose volume histogram with perioperative steroid. Int J Radiat Oncol Biol Phys. 2000;48:1461–1467
  20. Chen Z, Deng J, Roberts K, et al. Potential impact of prostate edema on the dosimetry of permanent seed implants using the new 131Cs (model CS-1) seeds. Med Phys. 2006;33:968–975
  21. Wang JZ, Mayr NA, Nag S, et al. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy. Med Phys. Apr 2006;33:1025–1032
  22. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605–614
  23. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  24. Snyder KM, Stock RG, Hong SM, et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;50:335–341
  25. Seltzer SM, Lamperti PJ, Loevinger R, et al. New national air-kerma-strength standards for 125I and 103Pd brachytherapy seeds. J Res Natl Inst Stand Technol. 2003;108:337–358
  26. Williamson JF, Butler W, Dewerd LA, et al. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy. Med Phys. May 2005;32:1424–1439
  27. Williamson JF, Coursey BM, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription. Med Phys. Apr 2000;27:634–642
  28. Beyer D, Nath R, Butler W, et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys. 2000;47:273–275
  29. Rivard MJ, Butler WM, Devlin PM, et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy. 2007;6:34–37
  30. Merrick GS, Butler WM, Tollenaar BG, et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys. 2002;52:461–468
  31. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;32:465–471
  32. RegGuide8.39. Release of patients administered radioactive materials. USA: NRC; 1997;1–19
  33. Horwitz EM, Vicini FA, Ziaja EL, et al. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys. 1998;41:267–272
  34. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:1487–1493

• Financial disclosure: The randomized trials included in this report were supported by research grants from IsoRay Medical, Richland, WA (IsoRay). When necessary, travel to attend one CAG meeting was provided by IsoRay. An honorarium was paid by IsoRay to some of the members to attend one of the meetings (SB, BM, RP, MR). Several members are paid consultants for IsoRay (BP, MR, SK, RP). None of the authors are employees, none have received any stock ownership, nor provided expert testimony, nor patent applications for IsoRay.

☆☆ Although IsoRay provided funding for the clinical trials referred to in the report, IsoRay provided no assistance with study design, data collection, analysis, data interpretation, report writing, or decision to submit the report for publication.

PII: S1538-4721(08)00589-8

doi: 10.1016/j.brachy.2008.05.004

Brachytherapy
Volume 7, Issue 4 , Pages 290-296 , October 2008

Article Tools

* Image Usage & Resolution